PW Medtech Group Limited disclosed on 9 September 2026 that it repurchased 402,000 ordinary shares on-market at prices ranging between HKD 0.97 and HKD 0.98 per share, deploying HKD 0.39 million in aggregate. All repurchased shares are intended for cancellation.

Including this latest transaction, the company has bought back a cumulative 3.71 million shares since the current mandate was approved on 26 June 2026. The cumulative repurchases represent approximately 0.26 % of PW Medtech’s issued share capital of 1.43 billion shares, well within the 144.29 million-share limit authorised by shareholders.

The issued share count remained unchanged at 1.43 billion as of 9 September 2026 because none of the repurchased shares had yet been cancelled. PW Medtech’s buybacks have been executed at prices ranging from HKD 0.91 to HKD 1.10 per share between 29 June and 9 September 2026.

Under Hong Kong Stock Exchange rules, the company is subject to a moratorium on issuing new shares until 9 October 2026 following the most recent repurchase. PW Medtech confirmed that all repurchases were conducted in compliance with the exchange’s regulations and the terms of its April 24 Explanatory Statement.